Brief: Takeda Pharmaceutical and ASKA Pharmaceutical enter into licensing agreement for relugolix in women's health indications

ASKA Pharmaceutical Holdings

31/05/2018 07:30

May 31 (Reuters) - Takeda Pharmaceutical Co Ltd  4502.T  
    
    * Says it and ASKA Pharmaceutical Co Ltd  4514.T  announced
today
that they entered inter a licensing agreement to grant ASKA
exclusive commercialization right for uterine fibroids and
exclusive development and commercialization rights for
endometriosis for Japan to maximize the product value of
Takeda-owned relugolix
    * Based on this agreement, Takeda will receive upfront
payment for
granting the exclusive commercialization right for uterine
fibroids and the exclusive development and commercialization
rights for endometriosis in Japan as well as holding the right
to receive royalties on sales

    
    Source text in Japanese:https://goo.gl/YgTMjT
    Further company coverage: 4502.T  4514.T 

 (Beijing Headline News)
 ((Beijing.HeadlineNews@thomsonreuters.com; +8601082555111;
Reuters Messaging: Pingping.Li1@thomsonreuters.com@reuters.net))